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Abstract  
Malaria is one of the most important infectious diseases with high morbidity rates particularly 
in young children and in pregnant women in Sub-Saharan Africa. Intermittent preventive 
treatment in pregnancy (IPTp) is an effective way to reduce morbidity of malaria in 
pregnancy and to reduce neonatal morbidity. Sulphadoxine/pyrimethamine (SP) is the 
recommended drug for IPTp in sub-Saharan Africa. Because of increasing resistance against 
SP there is a need to develop alternative drugs to replace SP for IPTp. Among the most 
promising candidate drugs in clinical development are mefloquine and azithromycin. Besides 
their antimalarial activity, these antimalarial drugs show significant antibacterial activity 
when given as IPTp. This antibacterial activity may offer several additional public health 
benefits when used as IPTp in pregnant women. These drugs may– besides protecting from 
malaria in pregnancy - treat and prevent often undetected sexually transmitted diseases 
(STDs) and urinary tract infections (UTIs).  
In this thesis, three studies are presented focusing on infectious diseases highly prevalent in 
sub-Saharan Africa. In the first study, the activity of mefloquine and azithromycin was 
assessed in vitro in comparison to sulphadoxine-pyrimethamine against bacterial pathogens 
with clinical importance in pregnancy. Results of this study demonstrated that SP was highly 
active against Staphylococcus aureus and Streptococcus pneumoniae. All tested Gram-
positive bacteria, except Enterococcus faecalis, were sensitive to azithromycin. Additionally, 
azithromycin was active against Neisseria gonorrhoeae. Mefloquine showed good activity 
against pneumococci but lower in vitro activity against all other tested pathogens. These data 
indicate that the use of azithromycin may be associated with most collateral benefit in curing 
and preventing concomitant bacterial infections. 
In the second study the impact of routine IPTp with mefloquine (MQ) and SP on 
Streptococcus agalactiae (GBS) was evaluated. GBS is an important cause of early neonatal 
infections leading to considerable morbidity and mortality. In this nested randomized 
controlled clinical trial GBS colonization rates in pregnant women were assessed. The overall 
prevalence of recto-vaginal GBS colonization was comparable to published findings in 
industrialized countries. Demographic characteristics showed significant association between 
GBS colonization and literacy. No difference of maternal GBS colonization was observed 
between SP- and MQ-IPTp regimes. This finding indicates that SP-IPTp was not superior to 
MQ-IPTp in preventing GBS colonization in pregnant women in Gabon.  
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In another analysis of the above described IPTp study, the prevalence of human herpes virus 8 
(HHV-8) infections was assessed in Gabon. HHV-8 infection is associated with Karposi-
sarcoma, Castleman disease and other malignant conditions and is known to be highly 
prevalent in Central Africa. In this sero-epidemiological study it was shown that 39% of 
pregnant women were seropositive for HHV-8 infections. Among 35% of seropositive 
women, real time PCR showed one pregnant women with detectable viraemia in peripheral 
blood. In analysis of cord blood samples of sero-positive women, no vertical transmission of 
HHV-8 was observed.  
Finally, a pharmacokinetic analysis of albendazole for the treatment of extra-hepatic 
echinococcosis is presented. Echinococcosis is highly prevalent in sub-Saharan Africa and 
medical treatment is one option in resource limited settings. Here the ability of albendazole 
and its active metabolite albendazole sulphoxide to penetrate into Echinococcus granulosus 
cysts of patients with non-liver cysts was investigated. Analysis of two patients with lung and 
soft tissue cysts demonstrated a satisfactory penetration of albendazole sulphoxide into 
Echinococcus cysts. These data underline the usefulness of albendazole therapy in extra-
hepatic cystic echinococcosis. 
 
  
9 | P a g e  
 
Zusammenfassung 
Malaria ist global gesehen eine der wichtigsten Infektionserkrankungen, die zu hoher 
Morbidität und Mortalität besonders unter jungen Kindern und Schwangeren im Afrika 
südlich der Sahara führt. Die intermittierende präventive Therapie in der Schwangerschaft 
(intermittent preventive treatment in pregnancy, IPTp) ist ein wirksames 
Präventionsprogramm, um die Morbidität der Malaria in der Schwangerschaft zu reduzieren. 
Sulphadoxin/Pyrimethamin (SP) ist das empfohlene Medikament für IPTp in Afrika südlich 
der Sahara. Aufgrund zunehmender Resistenz gegen SP besteht der Bedarf für eine 
Alternative zu SP. Zu den vielversprechendsten Kandidaten, die sich derzeit in klinischer 
Entwicklung befinden, zählen Mefloquin und Azithromycin. Neben ihrer Wirkung gegen 
Malaria zeigen diese Wirkstoffe auch eine bedeutende antibakterielle Aktivität. Diese 
antibakterielle Wirkung könnte bei Anwendung als IPTp bei Schwangeren einen zusätzlichen 
Nutzen darstellen. So könnte mit diesen Medikamenten - neben einem Schutz vor Malaria in 
der Schwangerschaft - häufig unentdeckte sexuell übertragene und Harnwegsinfektionen  
vorgebeugt und behandelt werden.  
In dieser Arbeit werden drei Studien mit einem Fokus auf Infektionserkrankungen im Afrika 
südlich der Sahara vorgestellt. In der ersten Studie wurde die Aktivität von Mefloquin und 
Azithromycin in vitro im Vergleich zu Sulphadoxin-Pyrimethamin gegen bakterielle 
Pathogene von klinischer Relevanz in der Schwangerschaft untersucht. Ergebnisse dieser 
Studie zeigen, dass SP hoch aktiv gegen Staphylococcus aureus und Streptococcus  
pneumoniae ist. Alle getesteten Gram-positiven Bakterien mit Ausnahme von Enterococcus 
faecalis zeigten ein gutes Ansprechen Reaktion auf Azithromycin. Zusätzlich zeigte 
Azithromycin Aktivität gegen Neisseria gonorrhoeae. Mefloquin zeigte gute Wirksamkeit 
gegen Pneumokokken, aber niedrigere in vitro Aktivität gegen alle anderen getesteten 
Pathogene. Diese Ergebnisse weisen darauf hin, dass die Verwendung von Azithromycin den 
umfassendsten Schutz gegen bakterielle Infektionen bieten könnte. 
In der zweiten Studie wurde der Einfluss von IPTp mit Mefloquin (MQ) und SP auf 
Streptococcus agalactiae (GBS) untersucht. GBS ist eine bedeutende Ursache früher 
neonataler Infektionen , die zu signifikanter Morbidität und Mortalität führen. In dieser 
randomisiert-kontrollierten klinischen Studie wurden die GBS Kolonisationsraten 
schwangerer Frauen erhoben. Die Gesamt-Prävalenz rekto-vaginaler GBS-Kolonisation war 
vergleichbar mit publizierten Daten aus industrialisierten Ländern. Die demografischen Daten 
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zeigten eine signifikante Assoziation zwischen GBS-Kolonisation und Alphabetisierungsrate. 
Zwischen SP- und MQ-IPTp Gruppen fand sich kein Unterschied in der maternalen GBS-
Kolonisation. Diese Ergebnisse zeigen, dass SP-IPTp bei der Prävention einer GBS-
Kolonisation keine Vorteile unter schwangeren Frauen in Gabun zeigte. 
In einer weiteren Analyse der oben beschriebenen Studie wurde die Prävalenz der Infektion 
mit dem humanen Herpesvirus 8 (HHV-8) in Gabun untersucht. HHV-8-Infektionen stehen in 
Verbindung mit Karposi-Sarkomen, Castleman Disease und anderen malignen Erkrankungen 
und ist in Zentralafrika bekanntermaßen hochprävalent. Unter 35% sero-positiven Frauen 
konnte mittels Real Time PCR bei einer schwangeren Frau HHV-8 mit nachweisbarer 
Virämie im peripheren Blutkreislauf nachgewiesen werden. Bei der Analyse von 
Nabelschnurblut-Proben von seropositiven Frauen konnte keine vertikale Übertragung von 
HV-8 beobachtet werden. 
Die letzte Studie beschäftigte sich mit der medikamentösen Therapie der Echinokokkose. Die 
Echinokokkose ist in weiten Teilen Afrikas hochendemisch und Albendazol ist eine 
medikamentöse Therapieoption. Bisher gibt es aber nur beschränkt Daten zur 
Zystenpenetratio von Albendazol. In dieser Studie wurde die Fähigkeit von Albendazol und 
dessen aktivem Metaboliten Albendazol Sulphoxid untersucht, in Echinococcus granulosus 
Zysten von Patienten mit extrahepatischen-Zysten zu penetrieren. Die Analyse von zwei 
Patienten mit Lungen- und Weichgewebe-Zysten zeigte einen zufriedenstellenden Übertritt 
von Albendazol Sulphoxid in Echinococcus Zysten. Diese Ergebnisse unterstreichen die 
Nützlichkeit der Albendazol-Behandlung bei zystischer Echinokokkose.  
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Aims 
The main objectives of the studies presented in the framework of this thesis were to gain 
better information regarding IPTp in sub-Saharan Africa, to investigate the epidemiology of 
other infectious diseases during pregnancy in the same region and to evaluate the impact of 
IPTp on infectious diseases other than malaria. 
 
The aims were: 
- To assess the anti-bacterial activity of sulphadoxine/pyrimetamine, mefloquine and 
azithromycin against common Gram-positive and Gram-negative bacteria in vitro.  
- To evaluate the efficacy of IPTp drugs against GBS colonization and to describe the 
prevalence of GBS colonization in pregnant women adhering to IPTp in Gabon. 
- To review the epidemiology and management of Group B Streptococcal colonization 
during pregnancy in African country Gabon 
- To describe the prevalence of HHV-8 infection in pregnant women in Gabon  
Another attempt was made to assess the ability of albendazole and its active metabolite 
albendazole sulphoxide to penetrate into cysts of two patients with extra-hepatic E. 
granulosus cysts – a zoonosis highly prevalent in some regions of Africa. 
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1. Introduction 
1.1 Malaria 
Malaria is an infectious disease caused by the parasite Plasmodium. Humans are intermediate 
hosts and mosquitoes the definitive hosts. In 1880, the French scientist “Alphonse Laveran” 
was the first to describe that the single-celled parasite from the genus Plasmodium as the 
causative agent of malaria. Malaria is a major public health problem in tropical and sub-
tropical areas of the world, where it affects millions of people. According to the “World 
Health Organization (WHO)” an estimated 207 million cases of malaria occurring in 2012 led 
to 627.000 deaths. Ninety percent of these deaths occur in sub-Saharan Africa, mostly among 
children younger than five. Pregnant women, people with HIV/AIDS, and international 
travelers are additional risk groups [1].   
There are numerous Plasmodium species that produce malaria in various animals’ species. 
However, six species commonly infect humans [2-4].  
1. Plasmodium falciparum is by far the deadliest of the human malarial species. P. 
falciparum infections may lead to severe diseases with progressive anemia, cerebral 
malaria, and other organ dysfunctions.   
2. Plasmodium vivax is the geographically most widespread species and is traditionally 
thought to produce fewer complications. However P. vivax may lead to respiratory 
distress and relapses leading to debilitating symptoms.  
3. Plasmodium malariae infections not only produce typical malaria symptoms but also 
can persist in the blood for very long periods, possibly decades, without ever 
producing symptoms.  
4. Plasmodium ovale cause fewer cases and less severe forms of the disease. Recently 
the P. ovale species complex was further subdivided into P. ovale wallikeri and P. 
ovale curtisi.  
 
In recent years, some human malaria cases have occurred with Plasmodium knowlesi – a 
species that causes malaria certain monkeys in South-East Asia [1].  
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The second line of recommended treatment is artesunate plus tetracycline, quinine plus 
tetracycline or doxycycline or clindamycin. Antimalarial treatment for uncomplicated P. 
vivax infection is chloroquine combined with primaquine [5]. 
1.2 Malaria in Pregnancy (MIP) 
Malarial infection during pregnancy is a huge public health problems, associated with low 
birth-weight [6-8], pre-term delivery [9] and maternal anaemia [10] and leads therefore to 
increased maternal, perinatal, and neonatal morbidity and mortality in pregnancy and  
puerperium in sub-Saharan Africa [11, 12].  
WHO recommends the use of IPTp with sulfadoxine-pyrimethamine (SP-IPTp) to reduce 
adverse health outcomes for pregnant women and their offsprings [13, 14]. However, due to 
an increasing rate of drug resistance of Plasmodium falciparum against SP, alternative 
antimalarial drugs have been evaluated for potential use as IPTp [15]. An ideal anti-malarial 
drug or drug combination for IPTp should be safe, well tolerated, and efficacious in the 
clearance of malaria parasites and provide a long period of chemoprotection. These drugs 
include amodiaquine, azithromycin, mefloquine, and combinations of these drugs with 
artemisinin derivatives or chloroquine [16, 17]. 
1.2.1 Sulphadoxine/Pyrimethamine (SP) 
Sulphadoxine (C12H14N4O4S) is a sulfonamide with a molecular weight of 310.3; it is 
soluble in water. Sulphadoxine is rapidly absorbed from the gastrointestinal tract. The 
elimination half-time (T1/2) is 4 to 9 days. Sulphadoxine is about 94% bound to plasma 
proteins. It is widely distributed to body tissues and fluids, passes into the foetal circulation 
and is detectable in breast milk.  The side effects of sulphadoxine are similar to other 
sulfonamides. The most important adverse effect is allergic reaction to the compound; these 
hypersensivity reactions may affect different organ systems.  The symptoms can be severe 
and include pruritus, photosensitivity reactions, exfoliative dermatitis, erythema nodosum, 
toxic epidermal necrolysis and Stevens-Johnson syndrome [18]. Other adverse effects include 
nausea, vomiting, anorexia, diarrhoea, fever, and interstitial nephritis, a syndrome resembling 
serum sickness, hepatitis, myocarditis, pulmonary eosinophilia, fibrosing alveolitis, peripheral 
neuropathy and systemic vasculitis.  
Pyrimethamine (C12H13ClN4) is a diaminopyrimidine with a molecular weight of 248.7, 
used in combination with a sulfonamide, usually sulphadoxine, or dapsone. Pyrimethamine is 
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1.2.4 Antibacterial activity of IPTp drugs 
IPTp aims to reduce the burden of malaria by administering treatment doses of antimalarial 
drugs. Besides antiplasmodial activity, SP, mefloquine and azithromycin have proven 
antibacterial activity. The bactericidal activity of these drugs when used as IPTp in pregnant 
women may offer several additional public health benefits.  
 Sulphadoxine/Pyrimethamine: is an antifolate antibiotic, which has an antibacterial activity 
against Streptococcus pneumoniae, Staphylococcus aureus, and Escherichia coli, therefore it 
is an important treatment in urinary tract, skin and soft tissue infections [34, 35]. 
Azithromycin: was shown to be effective against bacteria causing sexually transmitted 
diseases like Neisseria gonorrhea [36] and Chlamydia trachomatis [37]. Since 1999, it has 
been used for chemoprophylactic (1,000 mg) and curative (2,000 mg) treatment against 
syphilis. Azithromycin is also sensitive against Streptococcus pneumonia [38].  
Mefloquine:  was demonstrated that it has an antibacterial activity against Gram-positive 
bacteria, including staphylococci, pneumococci and enterococci. However it exerted weaker 
activity against Gram negative bacteria and yeasts [39].  
1.3 Other infectious diseases in Sub-Saharan Africa 
1.3.1 Group B streptococcus – Streptococcus agalactiae 
Group B Streptococcus (GBS), also known as Streptococcus agalactiae, is best known as a 
cause of postpartum infection and as the most common cause of neonatal sepsis.  S. 
agalactiae is a Gram-positive bacterium with a narrow zone of beta haemolysis. The 
virulence of S. agalactiae is related to the polysaccharide toxin it produces. Immunity is 
mediated by antibodies to the capsular polysaccharide and is serotype-specific. Several 
serotypes are known: Ia, Ib, Ic, II, III, IV, V, VI, VII, and VIII.  
S. agalactiae infection is extremely rare in healthy individuals and is associated with 
following underlying diseases: diabetes mellitus, malignancy [40], cardiovascular and 
genitourinary abnormalities, neurologic deficits, cirrhosis, steroid use, AIDS, renal 
dysfunction, and peripheral vascular disease [41]. Group B streptococci are found commonly 
in the vaginal and gastrointestinal tract and have been found to colonize the urethra in both 
men and women without causing infection. Group B streptococci can also colonize the upper 
respiratory tract. Urinary tract infections are a common manifestation of group B 
streptococcal disease and are observed in both pregnant and non-pregnant adults. Other 
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presentations of group B streptococcal infection include pneumonia, skin and soft-tissue 
infections, septic arthritis, osteomyelitis, meningitis, peritonitis, and endo-ophthalmitis [42].  
Neonates can be infected by the organism vertically in utero or during delivery from the 
maternal genital tract. Although the transmission rate from mothers colonized with S. 
agalactiae to neonates delivered vaginally is approximately 50%, only 1-2% of colonized 
neonates go on to develop invasive group B streptococcal disease [43]. Neonatal group B 
streptococcal disease is divided into early and late disease. Early onset disease presents within 
the first 7 days of life. Late onset disease is defined as infection that presents between one 
week postpartum and age 3 months. Early onset and late onset diseases commonly include 
sepsis, pneumonia and meningitis.  The prevention of group B streptococcal infection in 
pregnancy requires intra-partum antimicrobial prophylaxis in term women with culture 
evidence of recent vaginal or rectal group B streptococcal infection [44]. Penicillin or 
ampicillin is the initial approach. However, some isolates have shown minimum inhibitory 
concentrations (MICs) approaching the upper limits of susceptibility for some of the beta-
lactam agents [45]. Clindamycin and erythromycin are standard in individuals with penicillin 
allergy.  
 
1.3.2 Human Herpes Virus 8 
The Herpesvirinea family is subdivided into three subfamilies: the Alpha-, Beta-, and 
Gammaherpesvirinea. Human Herpes Virus 8 (HHV-8) is a member of Gammahepesvirinea. 
The Gammaherpesvirinea subfamily contains two genera (a classification of closely related 
viruses) that include both the gamma-1 or Lymphocryptovirus (LCV) and the gamma-2 or 
Rhadinovirus (RDV) virus genera. HHV-8 is the only RDV discovered in humans and shows 
typical herpesvirus morphology with a central icosahedral capsid surrounded by a lipid 
bilayer [46, 47].  The capsid is composed of four structural proteins and three of them have 
significant homologies to alpha- and beta-herpes viruses. The analysis of the open reading 
frames K1 and K15 led to the identification of six viral subtypes (A, B, C, D, E and N) with 
marked clustering to geographic regions [48, 49] . HHV-8 infects several cell types, usually as 
a latent form. Lytic replication can take place in blood and tissues from Kaposi’s sarcoma and 
multicentric Castleman’s disease. The virus can be latently maintained in B lymphocytes and 
monocytes which may serve as a reservoir [50].  
Human herpes virus 8 (HHV-8) – also known as Kaposi’s sarcoma associated herpes virus 
(KSHV) – is the infectious agent causing Kaposi’s sarcoma [51-56], primary effusion 
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lymphoma [57], and multicentric Castleman's disease [58]. HHV-8 transmission is thought to 
occur primarily by sexual contact [52, 59, 60]. However, the high seroprevalence rates in 
children living in Africa and the Western and Eastern Mediterranean countries [61-64] 
suggest other epidemiologically relevant routes of transmission.  
The serologic prevalence of HHV-8 infection has been explored in most continents worldwide 
and in different populations at different levels of risk for HHV-8 infection. The prevalence 
rates varied depending on the geographic origin of the sera tested and the specific tests used to 
determine these prevalences; in particular, there was also a remarkable difference between the 
prevalence of antibodies against latent form antigens or lytic antigens.  
1.4 Echinococcosis 
Echinococcosis is a parasitic disease caused by the larval stage of tapeworms of the genus 
Echinococcus. It is a zoonosis highly prevalent in many parts of Africa.[65] There are two 
important sorts of diseases, which differ in presentation, behaviour and clinical management.  
1. Alveolar echinococcosis is caused by Echinococcus multilocularis, in which a 
multiversiculated tumour  forms, mainly in the liver. The asymptomatic incubation 
period is 5 to 15 years. Serological tests are helpful for diagnosis. However, the 
diagnosis is challenging and experience of clinicians, radiologist, and microbiologist 
are important for the first diagnosis. Lack of awareness of the disease often leads to 
misinterpretation of findings.  
2. Cystic echinococcosis is caused by Echinococcus granulosus, in which fluid filled 
cysts develop mainly in the liver and lung. The incubation period may take just as long 
as in the case of alveolar echinococcosis. The spectrum of symptoms depends on the 
following: 
• involved organs 
• size of cysts and their sites within the affected organ or organs 
• interaction between the expanding cysts and adjacent organ structures, particularly bile 
ducts and the vascular system of the liver 
• complications caused by rupture of cysts 
• bacterial infection of cysts and spread of protoscolices and larval material into bile 
ducts or blood vessels 
• immunologic reactions such as asthma, anaphylaxis, or membranous nephropathy 
secondary to release of antigenic material 
  
 1.4.1 Echinococcus granulos
The adult E. granulosus is 3 to
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1.4.2 Echinococcus granulosus – Diagnosis and Treatment 
Diagnosis: There are several different serological methods for detecting antibodies. Among 
these, indirect haemagglutination (IHA), indirect fluorescent antibody (IFA) tests and enzyme 
immunoassay (EIA) are the most sensitive methods. Sensitivity rates of these methods range 
from 60% to 90%. IHA test and enzyme-linked immunoassay are the most widely used 
methods for detection of anti-Echinococcus IgG antibodies. Positive reactions in these 
methods usually have to be confirmed by a more specific method, such as a Western Blot 
(WB) for example. 
Besides serological methods, medical imaging is crucial in the diagnosis of human 
echinococcosis. Ultrasonography is a safe, non-invasive and cheap method for detecting and 
monitoring cysts in solid organs, especially the liver [66]. 
 In 2003, the World Health Organization proposed a standardized ultrasound classification 
based on the active-transitional-inactive status of the cyst as suggested by its sonographic 
appearance [67]. Computed tomography and magnetic resonance imaging are useful for other 
sites, such as rare cardiac lesions for example [68]. Simple X-ray can be useful for cysts in the 
lungs, bone, and muscle and for detecting calcified cysts.  
• Treatment: Mebendazole and albendazole are effective drugs against cystic echinococcosis. 
Both drugs are well tolerated but have different efficacy. Albendazole is more effective than 
mebendazole in the treatment of liver cysts. The cure rate of E. granulosus infection 
treatment with albendazole varies from 40% to 50%. Duration of therapy and doses are 
important. Before the introduction of antihelminthic drugs the first choice of treatment for 
echinococcosis was surgery. However, surgery is also associated with mortality (up to 2%), 
morbidity [69] and recurrence rates (2-25%) [70].  
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2. Material and Methods 
2.1 Chemicals and Agars 
Mueller Hinton broth, Merck KGaA, Darmstadt, Germany 
New York City agar, HiMedia™ Laboratories Pvt Ltd, India 
Chocolate agar, Becton Dickinson GmbH, Heidelberg, Germany 
Columbia broth base, Becton Dickinson GmbH, Heidelberg, Germany 
Neopeptone, Becton Dickinson GmbH, Heidelberg, Germany 
Agarose, Sigma-Aldrich, Seelze, Germany 
Haematin solution, Sigma-Aldrich, Seelze, Germany 
Tween, Sigma-Aldrich, Seelze, Germany 
Pyridoxal solution, Sigma-Aldrich, Seelze, Germany 
Amies transport medium, eSwab, Copan Diagnostics, Brescia, It. 
Lim Broth, Becton Dickinson, Germany 
Granada agar, Becton Dickinson, Germany 
SYBR Green I, Roche Diagnostic GmbH, Mannheim, Germany 
2.2 Pathogens and Drugs 
Escherichia coli, Clinical Isolate and American Type Culture Collection (ATCC) strain 
Enterococcus faecalis, Clinical Isolate and American Type Culture Collection (ATCC) strain 
Neisseria gonorrhoeae, Clinical Isolate and American Type Culture Collection (ATCC) strain 
Stahphylococcus aureus, Clinical Isolate and American Type Culture Collection (ATCC) 
strain 
Streptococcus agalactiae, Clinical Isolate and American Type Culture Collection (ATCC) 
strain 
Mefloquine, Sigma-Aldrich, Seelze, Germany 
Sulfadoxine/pyrimethamine, Sigma-Aldrich, Seelze, Germany 
Azithromycin, Sigma-Aldrich, Seelze, Germany 
Albendazole and Albendazole/Sulfoxide, Sigma-Aldrich, Seelze, Germany 
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2.3 Instruments 
“UltiMate 3000” system, Dionex, Sunnyvale, CA 
“Hypersil BDS-C18 column”, Thermo Fisher Scientific, Waltham, MA 
“Anaerobic chamber“,  BugBox, LedTechno, Heusden-Zolder, B. 
“QIAamp tissue kit”, Qiagen, Bechman Instruments Inc, US 
“KSHV/HHV-8 IgG IFA Kit”, Advanced Biotechnologies Inc, Columbia, US 
2.4 Techniques 
2.4.1 Minimal Inhibitory Concentration 
- The minimal inhibitory concentrations (MIC) of mefloquine, azithromycin, and SP 
were examined against the following bacterial pathogens  
a. Escherichia coli,  
b. Enterococcus faecalis,  
c. Neisseria gonorrhoeae,  
d. Staphylococcus aureus, 
e. Group B beta-hemolytic streptococci; i.e. Streptococcus agalactiae.  
- Bacteria were grown overnight at 37°C in Mueller Hinton broth with or without 2-5% 
horseblood.  
- Neisseria gonorrhoeae was incubated overnight at 35°C in an atmosphere containing 
5% CO2 on New York City agar and chocolate agar. 
- Drugs were obtained from Sigma-Aldrich (Seelze, Germany) and were dissolved and 
diluted (1:2) to stock solutions.  
- Fastidious broth medium was prepared and consisted:  
o 35 g Columbia broth base,  
o 5 g glucose,  
o 5 g yeast extract,  
o 2 g neopeptone, 
o 0.75 g agarose dissolved in 960 ml of distilled water [71].  
o A total of 30 ml haematin solution (0.05% [wt/vol] in 0.1 M NaOH) and 5 ml 
Tween 80 (10% [wt/vol]) was then added.  
- The resultant broth was sterilized by autoclaving and 6 ml of pyridoxal solution (0.1% 
[wt/vol]) and 1.5 ml of NAD solution (1% wt/vol) were added. 
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2.4.2 Determination of MICs 
- MICs were determined by using a standard microdilution assay with a bacterial 
turbidity of 0.5 McFarland (Clinical and Laboratory Standards Institute (CLSI) 
guidelines). 
- The bacterial density was approximately 105 CFU/ml.  
- The 96-well plates were incubated for 24 h at 35°C in a moist atmosphere containing 
5% CO2.  
- Positive control wells contained microorganisms without antibiotics.  
- All tests were performed in duplicate and MICs were reported as arithmetic means. 
 
2.4.3 Classifications of anti-bacterial activity 
- CLSI consensus cut off levels were used for the categorization of anti-bacterial 
activity. CLSI recommendation :  
o Cut off levels for azithromycin; classification as sensitive, intermediate and 
resistant:  
 S. aureus ≤2 µg/ml, >2 - <8 µg/ml, ≥8 µg/ml;  
 S. pneumonia and S.agalactiae ≤0.5 µg/ml, >0.5 - <2 µg/ml, ≥ 2 µg/ml. 
 N. gonorrhoeae ; due to CLSI recommendations and the European 
committee on anti-microbial susceptibility testing (EUCAST);  
 ≤ 0.25 µg/ml; > 0.25 µg/ml - ≤ 0.5 µg/ml; > 0.5 µg/ml  
• E. coli and Enterococcus no cut off levels by CLSI and EUCAST, 
therefore the cut off levels of S. aureus were used: ≤2 µg/ml, >2 - <8 
µg/ml, ≥ 8 µg/ml for susceptible, intermediate and resistant, 
respectively.  
o Sulfadoxine/Pyrimethamine: No recommendations are available for SP by 
CLSI or EUCAST. Therefore, CLSI and EUCAST cut off levels for 
trimethoprim- sulfamethoxazole - due to comparable anti-bacterial 
pharmacodynamics in the class of antifolate antibiotics and similar molecular 
weights for trimethoprim and pyrimethamine (290 and 249, respectively) -  
were used. The CLSI cut off levels for classification as sensitive, intermediate 
and resistant are the following:  
• S. aureus and E.coli: ≤ 2 µg/ml; > 2 - < 4 µg/ml; ≥ 4 µg/ml,  
• S. pneumonia: ≤ 0.5 µg/ml; > 0.5 - < 4 µg/ml; ≥ 4 µg/ml.  
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o The EUCAST cut off levels for SP (trimethoprim/pyrimethamine):  
• S. agalactiae: ≤ 1 µg/ml;  > 1 - ≤ 2 µg/ml; > 2 µg/ml,  
• E. faecalis: < 0.03 µg/ ml; ≥ 0.03 µg/ml - ≤ 1 µg/ml, > 1 µg/ml 
- For mefloquine: No recommendations are available by CLSI or EUCAST, therefore 
the threshold of drug resistance was set considering available pharmacokinetic data in 
human patients and published in vitro inhibitory concentrations against Plasmodium 
falciparum [72-78]. Thus, the threshold for drug resistance was 0.265 µg/ml for 
mefloquine. 
2.4.4 Detection of GBS colonization 
o Study participants: Pregnant women participating in a multicenter study evaluating 
alternative drugs for intermittent preventive treatment of malaria in pregnancy 
(MIPPAD: “Evaluation of the safety and efficacy of mefloquine as intermittent 
preventive treatment of malaria in pregnancy (IPTp) (NCT 00811421).”) were invited 
to participate in this study.   
o Research ethic: The study was approved by the institutional ethics review board, and 
written informed consent was obtained from HIV-negative pregnant women 
permanently residing in the study area with a gestational age at the first visit of ≤ 28 
weeks. Exclusion criteria included known allergy to the study drugs, known clinical 
history of severe renal, hepatic, psychiatric or neurological diseases or antimalarial 
treatment in the preceding 4 weeks. After the study details had been explained and 
informed consent had been signed, participants were given a study number and 
randomized to SP or mefloquine IPTp.  
o Detection of group B streptococcus colonization:  
- The swabs were taken from the cervix and rectally from 557 women at 
delivery.  
- All samples were collected using nylon flocked swabs that were submerged 
into 1 ml of liquid Amies transport medium.  
- A total of 200µl of the transport medium of each of the cervical/rectal swabs 
was inoculated into 5 ml of Lim Broth (Todd-Hewitt broth, 1% yeast extract, 
15 µg nalidixic acid/ml and 10 µg colistin/ml) [79], which is selective for 
Gram positive bacteria.  
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- This culture was incubated under aerobic conditions at 37 °C for 24 hours and 
then sub-cultured for 24h on Granada agar [80] at 37 °C in an anaerobic 
chamber.  
- Granada agar was examined for yellow-orange pigment colonies that confirm 
the presence of GBS.  
- The statistical analysis was performed with a commercial software package 
(JMP 5.0, SAS Institute Inc., NC) 
 
2.4.5 Detection of HHV8 infection  
o Study Participants: Pregnant women participating in a multicentre study for the 
preventive treatment of malaria in pregnancy (MIPPAD: “Evaluation of the safety and 
efficacy of Mefloquine as Intermittent preventive treatment of malaria in pregnancy 
(IPTp) (NCT 00811421).”) were invited to participate in this study.  
o Research ethic: The study was granted ethical approval by the Institutional Review 
Board of the Centre de Recherches Médicales de Lambaréné at the Albert Schweitzer 
Hospital in Gabon. 
o Sample collection:  
- Blood samples from mother-child pairs were obtained at delivery after 
provision of informed consent.  
- Two millilitre of maternal peripheral blood was obtained together with a 
biopsy from the maternal side of the placenta.  
- After delivery cord blood and a biopsy from the foetal side were collected. 
Whole blood and placental biopsies were used for the detection of virus 
specific DNA by PCR.  
o Serological detection of  HHV8:  
- Blood samples were centrifuged at 2500 rpm for 10 minutes to remove plasma 
for the detection of specific antibody directed against latent nuclear antigen 
(LANA) of HHV-8. 
- Plasma samples were tested at a 1/20 dilution for the HHV-8-specific IgG by 
an indirect immunofluorescence assay [81] following instructions by the 
manufacturer.  
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- Specific HHV-8 antibodies binding to the antigen present in infected cells were 
visualized after incubation with Fluorescein Isothiocyanate (FITC) under a 
fluorescence microscope.  
o Detection of HHV8 by PCR:  
- DNA was extracted from maternal and cord blood and placental biopsies using 
QIAamp tissue kit.  
- DNA extracts were further assays by PCR using the LightCycler® arousel-
based system.  
- Amplification was carried out in a 15µl PCR master mix containing: 
 10pmol/µl of each primers specific for ORF25 region [82],  
 3mM of MgCl2, 1x Lightcycler® LightCycler® FastStart DNA Master 
SYBR Green I.  
 and 1,5µl of DNA.   
- After an initial 10-min denaturation at 95°C, 50 cycles were run for 10 sec at 
95°C; for 5 sec at 65°C and for 22 sec at 72°C. These cycles were followed by 
a 15 sec melting at 65°C and 30 sec cooling at 40°C.   
- Each PCR sample (15µl) was analyzed by electrophoresis on a 2 % Agarose 
gel, and the bands were visualized by ethidium bromide staining.  
- Data were recorded on paper record forms. An available software package was 
used for statistical analysis (JMP 7.0, SAS Institute Inc., NC).  
 
2.4.6 Concentration and Separation of albendazole and albendazole 
sulphoxide  
- Venous blood samples for drug analysis were taken from two patients before 
albendazole intake and during the intervention.  
- Concentrations of albendazole and albendazole sulphoxide in plasma and cyst fluid 
were measured by a validated high performance liquid chromatographic (HPLC) 
method using an “UltiMate 3000” system (Dionex, Sunnyvale, CA).  
- Separation of albendazole sulphoxide was carried out using a Hypersil BDS-C18 
column (Thermo Fisher Scientific, Waltham, MA) with an acetic acid/methanol 
mobile phase.  
- The limit of quantification for albendazole and albendazole sulphoxide was 0.063 and 
0.072 µg/ml, respectively.  
- Coefficients of accuracy and precision for both compounds were < 8 
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3. Results 
Anti-bacterial activity of intermittent preventive treatment of malaria in 
pregnancy: comparative in vitro study of sulphadoxine-pyrimethamine, 
mefloquine, and azithromycin 
The bacterial isolates were sub-cultured after thawing prior to susceptibility assays (n = 34). 
Median MIC values of SP against Gram-positive bacteria were as follows:  
- S. aureus 16 µg/ml,  
- S. agalactiae 24 µg/ml,  
- S. pneumoniae 4 µg/ml, and E. faecalis 12 µg/ml.  
However, the MIC values of SP against Gram negative bacteria were considerably higher:  
- N. gonorrhoeae 256µg/ml 
- E. coli 128 µg/ml 
SP showed high or intermediate activity against all tested Gram-positive bacteria, whereas E. 
coli and N. gonorrhoeae were classified as resistant to SP (Table 1 and Table 2).  
Table 1: Median minimal inhibitory concentrations (MIC) of anti-malarial drugs against 
Gram-positive and Gram-negative bacteria. 
Microorganisms Median Minimal Inhibitory Concentration (µg/ml) 
 Sulphadoxine/Pyrimethamine Mefloquine Azithromycin 
S. aureus (n = 5) 16 16 0.5 
S. agalactiae (n = 4) 24 16 0.06 
S. pneumoniae (n = 5) 4 0.06 0.01 
E. faecalis (n = 5) 12 16 4 
N. gonorrhoeae (n = 10) 256 8 0.01 
E. coli (n = 5) 128 128 4 
Thresholds for drug resistance:  
Mefloquine: sensitive: ≤ 0.265 µg/ml;  
Sulphadoxine/Pyrimethamine (threshold based on fractional pyrimethamine concentration in 1:20 
combination): sensitive, intermediate, resistant,  
- S. aureus and E. coli: ≤ 2 µg/ml; > 2 - < 4 µg/ml; ≥ 4 µg/ml, 
- S. pneumonia: ≤ 0.5 µg/ml; > 0.5 - < 4 µg/ml; ≥ 4 µg/ml, 
- S. agalactiae: ≤ 1 µg/ml; > 1 - ≤ 2 µg/ml; > 2 µg/ml, 
- E. faecalis: ˂ 0.03 µg/ml; ≥ 0.03 - ≤ 1 µg/ml; > 1 µg/ml. 
Azithromycin: sensitive, intermediate, resistant 
- S. aureus; E. coli and E. faecalis ≤ 2 µg/ml, > 2 - < 8 µg/ml, ≥ 8 µg/ml; 
- S. pneumonia and S. agalactiae ≤ 0.5 µg/ml, > 0.5 - < 2 µg/ml, ≥ 2 µg/ml; 
- N. gonorrhoeae ≤ 0.25 µg/ml; > 0.25 µg/ml - ≤ 0.5 µg/ml; > 0.5 µg/ml; 
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All bacterial isolates were assessed for their in vitro drug susceptibility against 
mefloquine. The MIC values of mefloquine against Gram positive and Gram negative 
bacteria were as followed:  
- S. aureus 16 µg/ml,  
- S. agalactiae 16 µg/ml,  
- S. pneumoniae 0.06 µg/ml, 
- E. faecalis 16 µg/ml, 
- N. gonorrhoeae 8 µg/ml 
- E. coli 128 µg/ml 
Based on these data S. pneumonia was classified as sensitive, whereas S. aureus, S. 
agalactiae, E. faecalis, N. gonorrhoeae, and E. coli as resistant to the in vitro activity of 
mefloquine (Table 1 and Table 2). 
In vitro anti-bacterial activity of azithromycin against bacterial isolates was as followed: 
- S. aureus 0.5 µg/ml,  
- S. agalactiae 0.06 µg/ml,  
- S. pneumoniae 0.01 µg/ml, 
- E. faecalis 4 µg/ml, 
- N. gonorrhoeae 0.01 µg/ml 
- E. coli 4 µg/ml4 
Median MIC values of azithromycin showed that N. gonorrhoeae, S. aureus, S. agalactiae 
and S. pneumonia were sensitive to Azithromycin. The activity of Azithromycin against E. 
faecalis was weak. E. coli showed intermediate drug susceptibility against azithromycin 
(Table 1 and Table 2).  
Table 2: In vitro anti-bacterial activity of sulphadoxine-pyrimethamine, mefloquine, and 
azithromycin. 
 Sulphadoxine/Pyrimethamine Mefloquine Azithromycin 
S. aureus + - + 
S. agalactiae ~ - + 
S. pneumoniae + + + 
E. faecalis ~ - ~/- 
N. gonorrhoeae - - + 
E. coli - - ~ 
Insufficient in vitro activity; ~ intermediate in vitro activity; + good in vitro activity 
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Prevention of Group B Streptococcus Colonization by Intermittent Preventive 
Treatment of Malaria in Pregnant Women in Gabon: A Nested Analysis of a 
randomized Controlled Clinical Trial of Sulphadoxine-Pyrimethamine versus 
Mefloquine 
During the study period, 557 pregnant women participate in this sub-study and recto-vaginal 
swabs were taken. 346 participants had previously received mefloquine as IPTp and 186 were 
in the SP group. Baseline characteristics of participants including age, gravidity, anaemia, and 
literacy as well as delivery outcomes and birth weight of infants were collected and analysed.   
Table 1: Baseline Characteristic of Participants 
 Total  
 
N 
Percent of Group B Streptococcal 
Colonization 
 
 Positive (%)                        Negative (%) 
Relative Risk (95% 
Confidence Interval) 
 
Age, years 
14-17 77 18 82 1 
18-20 138 15 85 0.80 (0.38-1.69) 
21-24 116 22 78 1.3 (0.63-2.68) 
25-30 112 21 79 1.22 (0.59-2.56) 
31-49 114 22 78 1.26 (0.61-2.62) 
Literacy  
yes 441 17 83 1 
no 116 31 69 2.23 (1.40-3.56) 
Gravidity 
primigravida 131 13 87 1 
sekundigravida 198 18 82 1.43 (0.77-2.70) 
multigravida 228 25 75 2.28 (1.26-4.12) 
Anaemia 
no 155 21 79 - 
moderate 393 19 81 - 
severe 5 20 80 - 
Rapid plasma regain (RPR) 
positive 7 14 86 - 
negative 535 19 81 - 
Study drugs (IPTp) 
MQ 346 19 81 1 
SP 186 22 78 1.28 (0.83-1.98) 
Delivery- outcome 
Live Birth 536 19 81 1 
Stillbirth 14 14 86 0.69 (0.15-3.14) 
Spontenous abortion 5 40 60 6.23 (1.02-37.7) 
Birth weight- infants 
Normal birth weight 452 20 80 1 
Low birth weight 90 14 86 0.66 (0.35-1.25) 
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The prevalence of GBS colonization at delivery was 19.8% (110 of 557 participants). Risk 
factor analysis showed significant associations between GBS colonization and literacy of the 
pregnant women with prevalence rates of 31% (95% CI = 1.40-3.56); and 17% (95% CI= 1) 
in illiterate and literate women, respectively.  Importantly, 5 out of 557 pregnancies ended as 
spontaneous abortion, with 3 in GBS colonized women (95% CI = 1.02-37.7) and 2 in non-
colonized women (95% CI = 0.15-3.14). The occurrences rate of spontaneous abortion for 
GBS positive and GBS negative patients were 60% to 40%, respectively. 
Analysis of GBS colonization rates in the two IPTp groups showed prevalence of 18% (MQ 
group) and 22% (SP group), respectively, indicating no significant difference between IPTp 
regimens. Similarly there was no difference in GBS prevalence at delivery in MQ full dose 
and split dose groups. 
Table 2: GBS colonization and IPTp groups 
 Total  
 
 
N 
Group B Streptococcal Colonization 
 
              Positive                          Negative 
    N                 %                N                 % 
Mefloquine (MQ) 
MQ Full dose 192/557 34                 19 158                34 
MQ Split dose 179/557 34                 18 145                32 
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Epidemiology of Human Herpesvirus 8 Infection in Gabon: A Cross-Sectional 
Survey of Pregnant Women at Delivery  
From May 2010 to October 2011, 366 pregnant women were serologically tested for HHV-8 
infection. Ninety-eight cord blood samples from seropositive women were collected for 
serological testing and 76 mother-child pairs were available for PCR analysis. 
Baseline characteristics of all study participants were age (median 24 years), literacy, 
gravidity (median 2), and birth weight of infants (median 3000g). Forty-five patients were 
below 18 years old (36%), 299 patients were above 18 years old (35%), and data of 22 were 
missing. Thirty-three percent of study participants have the first gravidity. 143 pregnant 
women (39%) tested positive in the serologic assay. There were no significant differences 
between illiterate (29%) participants and literate participants (36%). There was also no 
difference in HHV-8 sero-positivity between patients pregnant for the second time or those 
for the third or more times (38% vs. 35%). Sixty-two infants were born with low birth weight; 
however, low birth weight was not correlated with HHV-8 infection (Table 1).   
The cord bloods of infants of HHV8-positive mothers were tested. Thirty percent (30/98) 
were HHV-8 seropositive. No cord bloods of infants of seronegative mothers were tested.   
Seventy-six mother-child pairs were available for PCR analysis. In only one mother blood 
sample was HHV-8 specific DNA sequences detected. All other samples were found to be 
negative. 
Table 1: Baseline Characteristics of Study Participants 
 
 Total  
 
N 
Percent of HHV8 Infection 
 
Positive (%)                                       Negative (%) 
Age, years 
14-17 45 36 64 
18-20 92 37 63 
21-24 72 31 69 
25-30 67 39 61 
31-49 68 32 68 
Literacy  
yes 282 36 64 
no 62 29 71 
Gravidity 
primigravida 86 33 67 
sekundigravida 128 37 63 
multigravida 130 35 65 
Birth weight- infants 
Normal birth weight 276 35 65 
Low birth weight 64 32 67 
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Intra-Cystic Drug Concentration of Albendazole Sulphoxide in Patients with 
Echinococcus granulosus Cysts 
A 60-year-old woman of Turkish origin (Patient A) and a 30-year old Turkish citizen (Patient 
B) were participated in this study. Patient A had a cystic lesion in the proximal Musculus 
satorius of 7.5 cm diameter and patient B had a distinctive pleural effusion on the right side of 
the lung with transgression of the diaphragm. Both patients were treated with 400 mg 
albendazole to be taken twice daily with a fatty meal for 5 and 4 days before surgical removal, 
respectively.  
Albendazol sulphoxide concentrations were measured in plasma and in cystic fluid. HPLC 
measurement showed that the concentration of albendazol sulphoxide in pre-operative and 
intra-operative plasma samples were in the range of 0.10 and 1.3µg/ml. Cystic fluid samples 
were analysed and the albendazol sulphoxide concentration in cystic fluid samples was 0.16 
and 0.59µg/ml (Table 1). 
The relative intra cystic drug concentration was as following: patient A 48% and patient B 
156%. These data demonstrate that albendazole sulphoxide has acceptable tissue penetration 
into echinococcal cysts. 
 
Table 1: Albendazole sulphoxide (µg/ml) and relative intra-cystic drug concentration 
  
Pre-operative 
plasma 
 
Intra-operative 
plasma 
 
Cyst fluid 
 
Relative intra-
cystic drug 
concentration 
Patient A 
 
1.26 1.24 0.59 48% 
Patient B 0.18 0.10 0.16 156% 
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4. Discussion 
Anti-bacterial activity of intermittent preventive treatment of malaria in 
pregnancy: comparative in vitro study of sulphadoxine-pyrimethamine, 
mefloquine, and azithromycin 
This in vitro drug susceptibility study showed a broad spectrum of antibacterial activity of SP 
against all tested Gram positive bacteria and intermediate activity against E. coli. Among the 
two currently proposed alternative drugs for IPTp – mefloquine and azithromycin – the latter 
shows a similarly broad antibacterial spectrum of activity as SP but additionally also good 
activity against N. gonorrhoeae. Mefloquine activity was classified as high against 
pneumococci and intermediate against all other bacteria except E. coli.  
The evaluation of the antimicrobial activity of antimalarials in vitro provides the basis for 
further clinical evaluation. Based on our data a clinically important effect on certain bacterial 
co-infections in pregnant women may be anticipated for SP and azithromycin and to a lesser 
extent for mefloquine. Previous data show that bacterial infections including sexually 
transmitted diseases, pneumococcal infections, and S. agalactiae colonisation contribute 
significantly to adverse pregnancy outcome in sub-Saharan Africa [83]. Similarly, there is 
evidence for significant improvement of maternal and child health by routine administration 
of appropriate antimicrobial drugs during pregnancy [84]. Given that urinary and genital tract 
infections are an important cause for premature delivery, it may be speculated that the routine 
administration of SP and azithromycin as IPTp may confer a reduction in the rate of 
prematurity. Similarly, the potential for eradication of vaginal S. agalactiae colonization by 
IPTp with SP or azithromycin might prevent cases of neonatal sepsis. However, caution must 
be used when extrapolating data on in vitro activity of drugs to anticipated in vivo efficacy. 
Clinical efficacy will ultimately depend – besides the intrinsic antibacterial activity as 
assessed in this study – on drug absorption, drug concentrations at the target sites, and half-
lives of drugs. Additionally, a limitation of our study lies in the absence of validated 
thresholds for the in vitro activity of SP and mefloquine. The proposed levels are based on 
comparative thresholds of in vitro activity against P. falciparum and known pharmacokinetic 
characteristics of the drugs and need further clinical validation [71]. Based on the hypothesis 
of a collateral health benefit by the administration of antimalarials with antibiotic activity 
against relevant pathogens, it may seem desirable to choose the next IPTp drug based on both 
its antimalarial and antibacterial activity. Whether such an approach is justified or not is 
however at least to date unknown. Although it may look attractive to simultaneously treat 
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concomitant and potentially deleterious bacterial infections by routine administration of 
antimalarials, this strategy may also prove hazardous. Large scale use of drugs with 
antibacterial activity may speed up the process of selection of drug resistant bacterial isolates. 
Interestingly, there is evidence for the development of antibiotic drug resistance by cross 
resistance with antimalarial drugs [85]. Epidemiologic evidence linking the development of 
quinolone resistant Gram negative bacteria with large scale use of chloroquine and the recent 
development and spread of quinolone resistant N. gonorrhoea strains is an illustrative 
example for this phenomenon [86]. The threat of promoting drug resistance against commonly 
used antibiotics is particularly worrying for sub-Saharan Africa where microbiologic analysis 
of infections is rarely performed and alternative antibiotics for drug resistant pathogens are 
often not affordable. Therefore, future studies on alternative IPTp drugs should include 
evaluations of the clinical efficacy against concomitant bacterial infections and the impact of 
large scale use of IPTp on the development and spread of antibiotic drug resistance. 
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Epidemiology and Management of Group B Streptococcal Colonization during 
Pregnancy in Africa 
Epidemiology of GBS colonization 
Streptococcus agalactiae – often referred to as Group B streptococcus (GBS) – is a Gram-
positive bacterium that has been identified as a human pathogen since the early 1900s [87]. 
GBS is of particular medical importance during pregnancy and the postpartum period because 
it may lead to invasive disease in both mother and infant. Maternal colonization with GBS in 
the genitourinary and gastrointestinal tract and transmission to the infant during labour and 
delivery is an important cause of early neonatal morbidity and mortality [88, 89].  
Numerous studies report the prevalence of GBS in pregnant women living in high income 
regions. Maternal colonization rates range from 10-30% in the USA [90], 11-19.5% in 
Canada [91], 20% in New Zealand [92], and 6.5-36% in Europe [93]. In these studies 
prevalence of GBS colonization was associated with ethnicity, certain sub-regional 
differences, age, gravidity, socioeconomic factors, and sexual behaviour. Methodological 
differences in diagnosing GBS including sampling strategies and culture conditions may have 
influenced prevalence rates and direct comparability of study results is therefore problematic. 
To overcome methodological differences, standard culture conditions were published by the 
Centres for Disease Control and Prevention (CDC) to enhance GBS detection and improve 
comparability of individual studies [94-96]. 
 
GBS infections in pregnant women and newborns 
In pregnant women, GBS may cause urinary tract infection, which may progress to maternal 
sepsis. Similarly, GBS may be a cause of chorioamnitis, endometritis and puerperal wound 
infection [97, 98].  On a population level, mortality from GBS-related diseases in pregnant 
women is however comparably low. Controversially, pregnancy-associated GBS infection 
may lead to adverse pregnancy outcome and early infections in newborns within the first few 
days of life [99]. Two forms of GBS infections are distinguished in newborns. Early-onset 
disease is defined as isolation of GBS from normally sterile sites including blood and 
cerebrospinal fluid. Early-onset disease occurs within the first 24 hours of birth and until 7 
days of life. Early-onset disease follows vertical transmission of GBS in the birth canal or by 
direct transmission from maternal GBS infection. Approximately 80% of infants with early-
onset disease reportedly become ill within 24 hours In the United States [100]. The most 
important early-onset diseases in infants are bacteraemia, sepsis with or without pneumonia 
and meningitis resulting in high mortality. A clinical study in the USA demonstrated that 
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early-onset disease caused by GBS was characterized by bloodstream infection, pneumonia, 
and meningitis in 40%, 7%, and 6% of patients, respectively. The overall case fatality rate 
associated with early-onset disease was 4% in this report [99]. Established risk factors for 
early-onset disease include preterm labour (< 37 weeks gestation), prolonged rupture of 
membranes (≥ 18 hours), and maternal fever (≥ 38.0° C) [97, 101, 102].  
Late-onset disease occurs in infants between 7 days and 3 months of age. Infection follows 
vertical transmission from mother to their infants [103] or horizontal transmission [104]. 
Again bloodstream infection and meningitis are the most common clinical features but other 
sites of infection occur. The overall case fatality rate of late-onset disease is reportedly 
approximately 2.5% [99]. Risk factors for the occurrence of late-onset disease are not yet well 
understood.  
 
Prevention of GBS infections in the newborn  
Over the past three decades several clinical trials demonstrated that the use of intra-partum 
antibiotic prophylaxis decreased the risk of vertical GBS transmission by a reduction of GBS-
related disease in the first week of life. Therefore, many national guidelines in high income 
settings recommend universal GBS screening and antimicrobial treatment of all pregnant 
women between 35 to 37 weeks of gestation [90, 102, 105]. Oral penicillins are the first line 
treatment based on their comparably narrow antimicrobial spectrum and high activity against 
GBS. Erythromycin and clindamycin are suggested as alternatives, particularly in the case of 
suspected allergy to penicillin [90]. Intra-partum treatment (IP) is effective in reducing the 
risk of early-onset disease in newborns to colonized women and neonatal colonization. A 
clinical trial in the USA demonstrated that the use of antimicrobial intra-partum 
chemoprophylaxis reduced the incidence rate of early-onset disease caused by GBS from 1.7 
per 1000 live births in 1993 to 0.6 per 1000 in 1998 [99].  Since GBS is a non-invasive 
colonising agent, local disinfection has attracted considerable attention as a potential tool to 
eliminate GBS colonisation from the female genital tract. Chlorhexidine was evaluated in 
several clinical trials in Europe, Africa and the USA for this purpose. In a European trial, 
chlorhexidine application reduced the rate of hospital admission due to GBS in neonates. 
However, the effectiveness of vaginal disinfectant against GBS-related neonatal sepsis and 
meningitis was not shown [106]. Importantly, a study in Malawi reported that the disinfection 
of the birth-canal with chlorhexidine solution reduced GBS related neonatal mortality from 
17.9 to 7.8 per 1000 live births. In addition this intervention also had a positive impact on 
maternal postpartum GBS infection [107]. Although local disinfection proved less effective 
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than antimicrobial drug prophylaxis, one of its potential advantages is the feature not to 
promote the development and spread of drug resistance. Vaginal disinfection could therefore 
constitute a potential alternative prevention strategy for resource limited regions due to the 
ease of use and low cost.  
The development of effective vaccines against GBS would without any doubt constitute a 
major advantage for the prevention of GBS infections. The underlying mode of action for 
such vaccines is the induction of specific antibodies to capsular GBS polysaccharides that 
protect against invasive GBS disease in the mother and the newborn. To date, GBS 
polysaccharide antigens are tested as conjugate vaccines and promising results have been 
reported for rodent models [108]. Besides the uncertainty of the translation of these results to 
humans, more detailed knowledge about the prevalence of GBS subtypes in high and low 
income regions and potential cross-protection of strain specific epitopes are mandatory for 
further development of future vaccine candidates.   
 
Current evidence for GBS related diseases and prevention strategies for sub-Saharan 
Africa 
Several studies conducted in developing countries investigated the prevalence of maternal 
GBS colonization and some reported the distribution of GBS serotypes. Prevalence rates in 
various geographic regions ranged from 12 – 22% (India/Pakistan: 12%, Asia/Pacific 19%, 
sub-Saharan Africa 19%, Middle East/North Africa 22% , America 14%) [98]. Similarly, 
when focusing on sub-Saharan African countries, considerable variability of GBS prevalence 
was observed, probably due to differences in sampling strategies and microbiologic 
processing of samples. Reported prevalence rates in these countries varied between 1% and 
32% (Nigeria 20%, Ivory Cost 19%, Togo 4%, Gambia 22%, Mozambique 1% [96], Malawi 
16.5% [109], Zimbabwe 20-32% [110]). Stoll and Schuchat summarized 34 reports from 23 
developing countries and indicated that the overall prevalence of maternal GBS colonization 
was approximately 18%, which is within a similar range as reported for women in the United 
States and Europe [96]. Despite the absence of important differences in antimicrobial 
susceptibility between GBS serotypes, their relative distribution is of great importance for 
ongoing efforts to identify vaccine candidates for clinical development. Clinical studies 
demonstrated that strains Ia, Ib, II and III were the most commonly encountered serotypes in 
high income regions and interestingly, these serotypes were associated with early-onset 
disease [100, 111-113]. 
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Serotype III caused more than half of neonatal group B streptococcal disease and mortality 
[114]. To date, available data indicate a similar serotype distribution in high income regions 
and sub-Saharan Africa. Reporting from African regions indicates that serotypes Ia, II, III, 
and V were most frequently encountered [96, 115, 116]. Based on these studies further 
molecular characterisation of GBS isolates from sub-Saharan Africa is important to evaluate 
most suitable vaccine targets for potential future vaccines.  
To date, the incidence of invasive GBS infections is incompletely understood in many low 
income regions. One study from Malawi indicated an incidence of early onset sepsis caused 
by GBS of 0.92 per 1000 live births [117]. However, a significant proportion of deliveries 
occur outside hospitals in many parts of sub-Saharan Africa and infants developing early 
onset sepsis may succumb before attending a health care centre. Importantly, routine 
identification of GBS is lacking in most routine institutions in Africa. The risk for overall 
mortality and rates of prematurity in GBS colonization remains therefore incompletely 
understood. [115]. However, some studies indicate that maternal GBS colonization may 
constitute an important risk factor for unfavourable birth outcome including spontaneous 
abortion, preterm delivery, and low birth weight in Africa [118] [96]. Importantly these 
conditions may outweigh the direct effect of invasive GBS infections on a population level. 
For a better understanding of the importance of GBS on a population level, further detailed 
epidemiologic studies are therefore needed.  
Contrary to high income regions, prevention strategies for GBS colonised pregnant women 
are hampered by a lack of facilities for appropriate diagnosis in most countries in sub-Saharan 
Africa. Since routine screening is not performed in pregnancy, targeted interventions are not 
feasible. Since overall incidence of neonatal sepsis due to GBS carriage is low, routine 
administration of antimicrobial prophylaxis to all pregnant women is most probably not cost-
effective. In addition this approach may increase the selective pressure for specific drug 
resistance, which may prove particularly worrisome in regions with limited availability of 
second line antimicrobials. Whether routine vaginal disinfection may prove safe, effective, 
and cost-effective, needs to be further investigated. 
 
 
  
 
Prevention of Group B Streptococcus Colonization by Intermittent Preventive 
Treatment of Malaria in Pregnant Women in Gabon: A Nested Analysis of a 
randomized Controlled Clinical Trial of Sulphadoxine-Pyrimethamine versus 
Mefloquine 
This study investigates the epidemiology of pregnancy-associated GBS colonization in 
Central Africa. The data show that the prevalence rate of GBS colonization among pregnant 
women reached 20%, which was comparable with the rate of GBS colonization of pregnant 
women in industrialized countries. No association of GBS colonization was observed with 
risk factors such as gravidity and maternal age. However, colonization was positively 
associated with literacy. This finding indicates the connection between the maternal GBS 
colonization and the socioeconomic status of study population. Moreover, maternal GBS 
colonization has been demonstrated to play an important role in spontaneous abortion [119].  
This study shows that the occurrence of spontaneous abortion is also related with maternal 
GBS colonization.  According to literature, the prenatal screening for GBS in pregnant 
women between 35 to 37 weeks of gestation and intra-partum antibiotic prophylaxis reduces 
the incidence of neonatal diseases. The use of penicillin, which has a narrow spectrum of 
antimicrobial activity, was encouraged by CDC for treatment. Erythromycin and clindamycin 
are the alternatives to penicillin [120]. Few clinical trials from Sub-Saharan Africa exist to 
describe the GBS - related neonatal morbidity and mortality. The existing data indicate that 
maternal GBS colonization rates of pregnant women and incidence of invasive disease in their 
offspring are comparable to industrialized countries. However, in resource poor settings, 
infrastructure for diagnostics, peripartal chemoprophylaxis and adequate case management is 
mostly lacking [115, 121]. Therefore, most infections will remain undetected and untreated. 
Intermittent preventive treatment of malaria in pregnancy (IPTp) could effect on concurrent 
infectious diseases in pregnancy. SP - recommended by WHO as IPTp drug of choice - has a 
broad spectrum of antibacterial activity against Gram positive bacteria and intermediate 
activity against Gram negative bacteria. Among the alternative IPTp drugs, mefloquine is one 
of the most promising treatments against malaria in pregnancy; however, this in vitro drug 
susceptibility study showed a low antibacterial activity against Gram positive and Gram 
negative bacteria [122].  Because of routine IPTp treatment in many African countries and 
their effects as prophylaxis may solve the lack of detection and treatment of GBS colonization 
during pregnancy.  However, in this study no specific activity of SP and mefloquine on GBS 
colonization was demonstrated.   
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In conclusion, these data indicate that maternal colonization with GBS during pregnancy is an 
underestimated health problem of pregnant women and their newborns in Sub-Saharan Africa. 
Active screening and the recommended treatment must be implemented in these countries for 
preventing maternal GBS colonization and for protecting newborns from invasive diseases. 
Nevertheless, the vaccine development for maternal immunization against group B 
streptococcus will maximize potential benefits in all low income countries. 
Epidemiology of Human Herpesvirus 8 Infection in Gabon: A Cross-Sectional 
Survey of Pregnant Women at Delivery  
This study aimed to better understand the epidemiology of HHV8 infection during pregnancy 
in Sub-Saharan Africa. In this study, HHV8 infections were widespread among pregnant 
women reaching 39%. However, infection was not associated with socioeconomic status. 
Also age was not associated with HHV8 infection in pregnant women.  According to 
literature, herpes virus infections during pregnancy can lead to fatal results including 
spontaneous abortion, premature delivery, and miscarriage [123-125]. In this study, HHV8 
infection had no influence on birth outcomes. In the US and Europe, the major transmission 
route of HHV-8 infection is anal intercourse [52, 126]. However, the increased level of HHV-
8 prevalence during childhood in endemic areas like sub-Saharan Africa provides evidence of 
nonsexual horizontal transmission. During our study the cord blood samples from seropositive 
patients were tested for latent nuclear antigen of HHV8. This finding shows the possible 
passive transmission of maternal IgG. However, no transplacental transmission was 
determined in spite of using highly sensitive real-time PCR analysis.  In summary, the data 
indicate that the prevalence of HHV8 infection in pregnant women is high in Sub-Saharan 
Africa. In future studies nonsexual horizontal transmission routes of HHV-8 infection in sub-
Saharan Africa need to be investigated. 
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Intra-Cystic Drug Concentration of Albendazole Sulphoxide in Patients with 
Echinococcus granulosus Cysts 
These data reveal a comparatively good tissue penetration of albendazole sulphoxide into 
echinococcal cysts in human patients with approximately 50% variation compared to plasma 
drug concentrations. A previous report indicated maximum plasma levels for albendazole-
sulphoxide in the range of 0.45 to 2.96 µg/ml [127] and intra-cystic drug concentrations 
between 0.06 and 0.42 µg /ml [128]. Morris et al. reported approximately 20% intra-cystic 
concentration of albendazole sulphoxide in patients treated with 10 mg/kg albendazole for one 
month prior to operation [129]. Although these data are in line with our results for plasma 
drug concentrations, the relative intra-cystic drug concentration of albendazole sulphoxide 
was significantly higher in our patients. Interestingly, praziquantel, another antihelminthic 
drug with activity against tapeworms, led to a considerable increase in albendazole plasma 
levels. The activity against protoscolices was significantly higher in patients treated with a 
combination of albendazole and praziquantel [130].  So far, most pharmacokinetic data on 
target site drug concentrations derive from echinococcal cysts of the liver and information on 
intra-cystic drug penetration for other organs are scarce. Despite the limited number of 
patients in this study, our data indicate that drug penetration in cysts located in the pleural 
cavity and the skeletal muscle is comparable or potentially higher compared to previous data 
on liver cysts. Albendazole is used for treatment of human echinococcosis since the 1980s and 
– depending on the stage of the disease – continuous long-term albendazole therapy shows 
cure rates between 30% and 80%. Although the oral bioavailability of albendazole is 
characterized by significant variation, intra-cystic drug penetration seems less variable and 
comparable to plasma drug levels. Although many questions regarding the optimal medical 
treatment of echinococcosis remain, the use of albendazole has been shown to allow safer 
manipulation of liver cysts during surgery, thus minimizing the chance of recurrence. Based 
on our data this may similarly be true for cysts localized in other organs.[131, 132]. Further 
data on anthelminthic combinations therapy and the development of novel anthelminthic 
drugs with improved oral bioavailability are desirable to further improve the management of 
echinococcosis. 
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